Pharmaxon gains orphan drug status for PR-21

Fri, 10/07/2011

Pharmaxon announces that PR-21 has been granted orphan drug status for the treatment of acute spinal cord injuries by the European Medicines Agency.

AttachmentSize
PR360.23 KB